N-methyl-2-(4-(methylsulfonyl)piperazin-1-yl)ethanamine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: N-methyl-2-(4-(methylsulfonyl)piperazin-1-yl)ethanamine
• 英文别名: 1-methanesulfonyl-4-(2-methylamino-ethyl)-piperazine；N-methyl-2-(4-methylsulfonylpiperazin-1-yl)ethanamine
• 化学式: C₈H₁₉N₃O₂S
• 分子量: 221.324
• InChiKey: FLZLPCDSRSSGRI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.1
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  61
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  N-methyl-2-(4-(methylsulfonyl)piperazin-1-yl)ethanamine 、 methyl-(n-tetradecyl)-carbamic acid chloride 在 三乙胺 作用下， 以 1,4-二氧六环 、 二氯甲烷 、 水 为溶剂， 生成 N,N'-Dimethyl-N-(n-tetradecyl)-N'-[2-(1-methanesulfonyl-4-piperazinyl)-ethyl]-urea
  参考文献：
  名称：

  Basically substituted ureas and processes for the treatment of virus

  摘要：

  本发明涉及具有一般式I的新的基本取代脲类化合物及其药学上可接受的酸盐，这些化合物对DNA和RNA病毒具有改进的抗病毒活性。该发明还涉及通过给予含有这些脲类化合物或其盐的组合物作为活性剂来治疗受到病毒引起的人类或动物患病的情况。

  公开号：

  US04239761A1
• 作为产物：
  描述：

  N-羟乙基哌嗪 、 甲基磺酰氯 、 甲胺 在 三乙胺 作用下， 以 二氯甲烷 、 乙醇 为溶剂， 反应 24.0h， 以35%的产率得到N-methyl-2-(4-(methylsulfonyl)piperazin-1-yl)ethanamine
  参考文献：
  名称：

  [EN] PYRAZOLO[1,5-A]PYRIDINE AND IMIDAZO[1,2-A]PYRIDINE DERIVATIVES AND THEIR USE IN CANCER THERAPY
  [FR] DÉRIVÉS DE PYRAZOLO[1,5-A]PYRIDINE ET D'IMIDAZO[1,2-A]PYRIDINE ET LEUR UTILISATION EN THÉRAPIE ANTICANCÉREUSE

  摘要：

  该发明涉及吡唑并[1,5-a]吡啶和/或咪唑并[1,2-a]吡啶衍生物，其制备，其作为癌症预防或治疗药物的用途，可以单独使用，也可以与放射治疗和/或抗癌药物结合使用。

  公开号：

  WO2010074586A1

文献信息

• Benzothiazole Kinase Inhibitors and Methods of Use
  申请人：Intellikine LLC

  公开号：US20150225407A1

  公开（公告）日：2015-08-13

  The present invention provides chemical entities or compounds and pharmaceutical compositions thereof that are capable of modulating lipid kinases such PI3 kinases, tryosine kinases and protein kinases such as mTOR. Also provided in the present invention are methods of using these compositions to modulate these kinases especially for therapeutic applications.

  本发明提供了能够调节脂质激酶如PI3激酶、酪氨酸激酶和蛋白激酶如mTOR的化学实体或化合物以及其药物组合物。本发明还提供了使用这些组合物来调节这些激酶的方法，特别是用于治疗应用。
• Cyclic compounds
  申请人：Yamada Koichiro

  公开号：US20080027037A1

  公开（公告）日：2008-01-31

  1. A cyclic compound of the formula (I) or a pharmacologically acceptable salt thereof, wherein X is ═CH— or ═N—, Y is —NH—, —NR 4 —, —S—, —O—, —CH═N—, —N═CH—, —N═N—, —CH═CH—, etc., R 1 is a lower alkoxy group, an amino group, a heterocyclic ring containing N atom(s), or a hydroxy group substituted by a heterocyclic ring containing N atom(s) (each of which is optionally substituted), R 2 is a lower alkylamino group which is optionally substituted by an aryl group, a lower alkoxy group which is optionally substituted by an aryl group, a lower alkoxy group substituted by an aromatic heterocyclic ring containing N atom(s), R 3 is an aryl group, a heterocyclic ring containing N atom(s), a lower alkyl group, a lower alkoxy group, a cyclo lower alkoxy group, a hydroxy group substituted by a heterocyclic ring containing N atom(s), or an amino group (each of which is optionally substituted), and R 3 and a substituent in Y may be combined to form a lactone ring. The compound of the present invention has excellent selective PDE V inhibitory activity and therefore, is useful as a therapeutic or prophylactic drug for treating various diseases due to functional disorders on cGMP-signaling.

  公式（I）的环状化合物或其药学上可接受的盐，其中X为═CH—或═N—，Y为—NH—、—NR4—、—S—、—O—、—CH═N—、—N═CH—、—N═N—、—CH═CH—等，R1为较低的烷氧基、氨基、含N原子的杂环环或含N原子的杂环环取代的羟基（每个都可选地取代），R2为较低的烷基氨基，可选地取代芳基基团、可选地取代的较低的烷氧基、取代芳香族含N原子的杂环环的较低的烷氧基，R3为芳基基团、含N原子的杂环环、较低的烷基、较低的烷氧基、环状较低的烷氧基、含N原子的杂环环取代的羟基或氨基（每个都可选地取代），R3和Y中的取代基可结合形成内酯环。本发明的化合物具有优异的选择性PDE V抑制活性，因此，可用作治疗或预防因cGMP信号传导功能障碍引起的各种疾病的药物。
• BENZOTHIAZOLE KINASE INHIBITORS AND METHODS OF USE
  申请人：Ren Pingda

  公开号：US20110124641A1

  公开（公告）日：2011-05-26

  The present invention provides chemical entities or compounds and pharmaceutical compositions thereof that are capable of modulating lipid kinases such PI3 kinases, tryosine kinases and protein kinases such as mTOR. Also provided in the present invention are methods of using these compositions to modulate these kinases especially for therapeutic applications.

  本发明提供了化学实体或化合物及其制备的药物组合物，能够调节脂质激酶如PI3激酶、酪氨酸激酶和蛋白激酶如mTOR。本发明还提供了使用这些组合物调节这些激酶的方法，尤其是用于治疗应用。
• Basically substituted urea compounds, process for producing the same and pharmaceutical compositions containing the same
  申请人：Asta-Werke Aktiengesellschaft Chemische Fabrik

  公开号：EP0008696A1

  公开（公告）日：1980-03-19

  The present invention is related to new basically substituted ureas having the general Formula I and the pharmaceutically acceptable acid addition salts thereof which produce an improved antiviral activity against DNS- and RNS-viruses. The invention is further related to processes for producing the same as well as to compositions containing the same as active agent used in humans and animals suffering from diseases caused by viruses.

  本发明涉及具有通式 I 的新的基本取代的脲类化合物及其药物可接受的酸加成盐。 及其药学上可接受的酸加成盐，它们对 DNS 和 RNS 病毒具有更好的抗病毒活性。本发明还涉及生产上述物质的工艺以及含有上述物质的组合物，这些组合物作为活性剂用于治疗由病毒引起的人类和动物疾病。
• Disubstituted 1, 2, 4-triazine compound
  申请人：MITSUBISHI TANABE PHARMA CORPORATION

  公开号：US10029993B2

  公开（公告）日：2018-07-24

  This invention provides a novel disubstituted 1,2,4-triazine compound or a pharmaceutically acceptable salt thereof, which has an aldosterone synthetase inhibitory activity and is useful for preventing and/or treating various diseases or conditions associated with aldosterone; a method for preparing it; use of it; as well as a pharmaceutical composition comprising it as an active ingredient. A compound of the general formula [I]: wherein RA is, for example, a group of the following formula (A-1): wherein ring A1 is, for example, a cycloalkyl group which may be substituted, and RB is, for example, a monocyclic cycloalkyl group, or a pharmaceutically acceptable salt thereof.

  本发明提供了一种新型二取代1,2,4-三嗪化合物或其药学上可接受的盐，该化合物具有醛固酮合成酶抑制活性，可用于预防和/或治疗与醛固酮相关的各种疾病或病症；本发明还提供了一种制备方法；本发明的用途；以及一种以本发明为活性成分的药物组合物。通式[I]的化合物： 其中 RA 是例如下式（A-1）的基团： 其中，环 A1 例如是可被取代的环烷基，RB 例如是单环环烷基、 或其药学上可接受的盐。